EBF4 as A Cancer Target Or Biomarker: Potential Therapies and Diagnostic Tests

Target Name: EBF4

NCBI ID: G57593

EBF4

EBF4 as A Cancer Target Or Biomarker: Potential Therapies and Diagnostic Tests

EBF4 (Olf-1/EBF-like 4) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and gastrointestinal tract. It is a member of the EBF family of proteins, which are known for their ability to promote cell survival and proliferation. In recent years, researchers have become increasingly interested in the potential role of EBF4 as a drug target or biomarker.

The EBF4 gene was identified in the late 1990s as a potential candidate for a drug target due to its ability to induce cell survival in animal models of cancer. Studies have shown that inhibiting EBF4 has been effective in treating various types of cancer, including breast, lung, and ovarian cancer. Additionally, researchers have also found that high levels of EBF4 expression are associated with poor prognosis in cancer patients.

One of the reasons for the potential drug-related benefits of EBF4 is its ability to promote cell survival, which can lead to the formation of cancer stem cells. Cancer stem cells are a type of cell that have the ability to give rise to all different types of cancer cells, making them difficult to treat. However, studies have shown that EBF4 can promote the formation of cancer stem cells from normal cells. This may have implications for the development of cancer-related treatments.

Another potential mechanism by which EBF4 may contribute to cancer treatment is its role in cell signaling pathways. EBF4 has been shown to be involved in various signaling pathways, including the TGF-β pathway and the PI3K/Akt pathway. These pathways are involved in cell growth, survival, and angiogenesis, which are all important processes that contribute to the development and progression of cancer. By targeting these pathways, drugs that inhibit EBF4 may have the potential to treat a wide range of cancer types.

In addition to its potential role in cancer treatment, EBF4 has also been shown to be a potential biomarker for cancer. The expression of EBF4 has been shown to be associated with the development and progression of various types of cancer, including breast, lung, and ovarian cancer. Additionally, studies have shown that reducing EBF4 expression can be a reliable biomarker for cancer diagnosis and prognosis. This may have implications for the development of new cancer diagnostic tests or biomarkers.

Overall, the potential drug-related benefits of EBF4 as a cancer target or biomarker make it an important area of research. Further studies are needed to fully understand the role of EBF4 in cancer treatment and to develop new treatments that target this protein. By doing so, we may be able to improve the treatment outcomes for cancer patients.

Protein Name: EBF Family Member 4

Functions: Transcription factor (PubMed:35939714). Binds to specific sequence motif 5'-CCCNNG[GA]G-3' in regulatory elements of putative target immunoregulatory genes such as NKG7, GZMA, and TBX21 (PubMed:35939714). Positively modulates transcription of NKG7 (PubMed:35939714). May play a role in regulating FAS/CD95-mediated apoptosis in cytotoxic NK cells and T-cells, probably downstream of interleukin IL2 signaling (PubMed:35939714)

The "EBF4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about EBF4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets